Fig. 6.

Geometric mean concentrations of vilaprisan (± standard deviations) (VPR) and [¹⁴C]VPR in plasma after single oral and intravenous (i.v.) administration of VPR 4 mg (drug–drug interaction/microtracer study). All 14 subjects received a single oral dose of VPR 4 mg as a tablet and seven of these subjects additionally received a single i.v. dose of [¹⁴C]VPR 15.7 µg (37 KBq) [30-min infusion, 1 mL/min] starting 1.5–2 h after administration of the oral dose, i.e., around the time of the expected maximum plasma concentration of the oral dose